Antibody-Based Therapies for Peripheral T-Cell Lymphoma

• Published in: Cancers Vol. 16; no. 20; p. 3489
• Main Authors: Shafagati, Nazila, Paul, Suman, Rozati, Sima, Sterling, Cole H
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15-10-2024; MDPI
• Subjects: Antibodies; Antigens; B-cell lymphoma; Bispecific antibodies; Cell death; Cell survival; Cell therapy; Chemokines; Chimeric antigen receptors; Cytomegalovirus; Cytotoxicity; Dosage and administration; Drug therapy; FDA approval; Leukemia; Lymphocytes B; Lymphocytes T; Lymphoma; Malignancy; Medical prognosis; Monoclonal antibodies; Multiple myeloma; Response rates; Review; T cell lymphoma; Toxicity; Tumor necrosis factor-TNF; Tumors; Viral antibodies; United States; CAR T-cell therapy; bispecific T-cell therapy; CAR-NK cell therapy; T-cell lymphoma; bispecific NK cell therapy; immunotherapy
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16203489

While antibody-based immunotherapeutic strategies have revolutionized the treatment of B-cell lymphomas, progress in T-cell lymphomas has suffered from suboptimal targets, disease heterogeneity, and limited effective treatment options. Nonetheless, recent advances in our understanding of T-cell biology, the identification of novel targets, and the emergence of new therapies provide hope for the future. In this review, we explore four areas of current and evolving antibody-based strategies for the treatment of peripheral T-cell lymphoma (PTCL): monoclonal antibodies (mAbs), bispecific antibodies (BsAs), chimeric antigen receptor T-cell therapy (CAR-T), and antibody-drug conjugates (ADCs). As part of this discussion, we will also include limitations, lessons learned, and potential future directions.